Gastrointestinal segmental remission with oral budesonide therapy for eosinophilic gastrointestinal diseases
- 25 June 2024
- journal article
- editorial
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (10) , 2857-2860.e2
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Allergy and Infectious Diseases
This publication has 8 references indexed in Scilit:
- Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed BudesonideInternal Medicine, 2020
- Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experienceThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter ConsortiumAmerican Journal of Gastroenterology, 2019
- Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and VedolizumabDigestive Diseases and Sciences, 2019
- Prevalence of Eosinophilic Gastritis, Gastroenteritis, and ColitisJournal of Pediatric Gastroenterology and Nutrition, 2016
- Systematic review with meta‐analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population‐based studiesAlimentary Pharmacology & Therapeutics, 2015
- Histopathologic Features of Eosinophilic Esophagitis and Eosinophilic Gastrointestinal DiseasesGastroenterology Clinics of North America, 2014
- Eosinophilic enterocolitis diagnosed by means of technetium-99m albumin scintigraphy and treated with budesonide (CIR).Gut, 1994